From November 1998 to August 2004, Dr. John Wong was Chairman and CEO of MorphoGen Pharmaceuticals, Inc. MorphoGen was involved in developing its pluripotent adult-derived stem cells as therapeutic agents for transplantation therapies. He has founded an information technology company and numerous biotech companies. Prior to joining MorphoGen, Dr. Wong was President of SciFin, Inc., a Los Angeles-based consulting firm that specializes in: 1) identifying new platform technologies for commercialization; 2) raising capital for and funding both start-up and early stage biotech and healthcare-related companies; and, 3) developing and acquiring new technologies. Earlier, Dr. Wong was Vice President of Equity Research and the senior biotechnology analyst at Van Kasper & Company of San Francisco, California. In June 1997, Dr. Wong received recognition by The Wall Street Journal as an “All Star Analyst” in biotechnology.

Dr. Wong received a B.A. in zoology and a Ph.D. in immunology and medical microbiology from the School of Public Health at the University of California, Berkeley. He completed his postdoctoral training in infectious diseases and cellular immunology at the New York University School of Medicine and completed a hematology fellowship at Memorial Sloan-Kettering Cancer Institute in New York. Prior to entering the securities industry, Dr. Wong was assistant research professor of experimental pathology at the University of Southern California School of Medicine.

Dr. Henry E. Young is currently Professor of Anatomy and Professor of Pediatrics at the School of Medicine at Mercer University in Macon, Georgia. Dr. Young has devoted his entire scientific career to studying the basic mechanisms of tissue regeneration and stem cell biology. He has published numerous scientific papers on tissue repair and regeneration, fetal and adult stem cells, and holds patents on pluripotent stem cells and factors that influence stem cell differentiation. Dr. Young is the author and inventor of an issued patent, pluripotent mesenchymal stem cells, and a patent pending, pluripotent embryonic-like stem cells. These patents were assigned to MorphoGen Pharmaceuticals of which Dr. Young was a scientific founder.

Dr. Young received a B.S. in biology from Ohio State University, a M.S. in zoology from University of Arkansas, Fayetteville, and a Ph.D. in Anatomy at Texas Tech University Health Sciences Center in Lubbock, Texas. He completed his postdoctoral training in carbohydrate biochemistry at Case Western Reserve University in Cleveland. He held an instructorship in hybridoma technology at Rush Presbyterian St. Luke’s Medical Center in Chicago. Since 1988 he has been on faculty in the Division of Basic Medical Sciences in the School of Medicine at Mercer University in Macon, Georgia.

Dr. Young has recently discovered another novel stem cell that is more primitive than the pluripotent stem cells he has previously patented. He is currently prosecuting a patent concerning the composition of matter and future use of this novel cell, an adult-derived totipotent blastomere-like stem cell. Dr. Black, the other scientific founder of Moraga is a co-inventor of this new patent.

Dr. Asa C. Black, Jr. is currently Professor of Anatomy and Professor of Obstetrics and Gynecology at the School of Medicine at Mercer University in Macon, Georgia. Dr. Black has published numerous papers on fetal alcohol syndrome, neurobiology, and stem cell biology. He was a National Merit Scholar at Vanderbilt University. He was the recipient of a predoctoral fellowship from the National Institutes of Health at Vanderbilt University. He was awarded a postdoctoral fellowship from the National Institutes of Health at the University of Iowa, College of Medicine in Iowa City, Iowa. He has been awarded 10 research grants from the National Institutes of Health.

Dr. Black received a B.A. in chemistry and a Ph.D. in anatomy from Vanderbilt University, in Nashville, Tennessee. He received postdoctoral training in the Department of Anatomy at the University of Iowa, College of Medicine in Iowa City, Iowa. He was an assistant professor at the University of Iowa, College of Medicine before being appointed associate professor at Mercer University School of Medicine in 1985. He is currently involved in research on stem cells with Dr. Young.

Mr. Fish is currently chair of Rutan & Tucker's Intellectual Property and Technology Group. He started his legal career at Lyon & Lyon LLP in 1990, and developed his own practice from 1995 through 2001. Mr. Fish has attracted a world-class clientele in a wide array of fields, including mechanical engineering, medical devices, chemicals and pharmaceuticals, electronics, computer software, and business methods. Exemplary clients include Fluor Corp. and ICN Pharmaceuticals, both billion-dollar companies for which Mr. Fish has worked as primary US intellectual property counsel. Mr. Fish's group has also represented Honeywell in facilities throughout the United States, including California, Washington, Minnesota, Pennsylvania and Virginia. SRI International (previously known as Stanford Research Institute) employed Mr. Fish for several years in energy-related and computer software technologies.

Mr. Fish received his B.A. in natural sciences from University of Pennsylvania with graduate courses in medicine and electronics. He also obtained his J.D. cum laude from California Western School of Law.